Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Feb;84(4):465–469. doi: 10.1054/bjoc.2000.1624

A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma

F H Blackhall 1, M Ranson 1, J A Radford 1, B W Hancock 2, M Soukop 3, A T McGown 4, A Robbins 5, G Halbert 6; G C Jayson for the Cancer Research Campaign Phase I/II Committee1
PMCID: PMC2363763  PMID: 11263437

Abstract

Bryostatin 1 is a naturally occurring macrocyclic lactone with promising antitumour and immunomodulatory function in preclinical and phase I clinical investigations. In this phase II study, 17 patients with progressive non-Hodgkin's lymphoma of indolent type (NHL), previously treated with chemotherapy, received a median of 6 (range 1–9) intravenous infusions of 25 μg/m2bryostatin 1 given once weekly over 24 hours. In 14 evaluable patients no responses were seen. Stable disease was attained in one patient for 9 months. The principal toxicities were myalgia and phlebitis. Treatment was discontinued early because of toxicity alone (phlebitis) in 2 patients, toxicity in addition to progressive disease in 3 patients (myalgia and phlebitis n = 2; thrombocytopenia n = 1) and progressive disease in 5 patients. The results fail to demonstrate efficacy of this regimen of bryostatin 1 in the treatment of NHL. In light of preclinical data that demonstrate synergy between bryostatin 1 and several cytotoxic agents and cytokines, clinical studies to investigate bryostatin 1 in combination are warranted. We also present data to demonstrate that central venous lines may be used in future studies to avoid phlebitis. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: bryostatin 1, non-Hodgkin's lymphoma, protein kinase C inhibitors

Full Text

The Full Text of this article is available as a PDF (75.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Al-Katib A. M., Smith M. R., Kamanda W. S., Pettit G. R., Hamdan M., Mohamed A. N., Chelladurai B., Mohammad R. M. Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts. Clin Cancer Res. 1998 May;4(5):1305–1314. [PubMed] [Google Scholar]
  2. Basu A., Lazo J. S. Sensitization of human cervical carcinoma cells to cis-diamminedichloroplatinum(II) by bryostatin 1. Cancer Res. 1992 Jun 1;52(11):3119–3124. [PubMed] [Google Scholar]
  3. Berkow R. L., Schlabach L., Dodson R., Benjamin W. H., Jr, Pettit G. R., Rustagi P., Kraft A. S. In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity. Cancer Res. 1993 Jun 15;53(12):2810–2815. [PubMed] [Google Scholar]
  4. Buchner K. The role of protein kinase C in the regulation of cell growth and in signalling to the cell nucleus. J Cancer Res Clin Oncol. 2000 Jan;126(1):1–11. doi: 10.1007/pl00008458. [DOI] [PubMed] [Google Scholar]
  5. Cheung A. P., Hallock Y. F., Vishnuvajjala B. R., Nguyenle T., Wang E. Compatibility and stability of bryostatin 1 in infusion devices. Invest New Drugs. 1998;16(3):227–236. doi: 10.1023/a:1006187710029. [DOI] [PubMed] [Google Scholar]
  6. Elgie A. W., Sargent J. M., Alton P., Peters G. J., Noordhuis P., Williamson C. J., Taylor C. G. Modulation of resistance to ara-C by bryostatin in fresh blast cells from patients with AML. Leuk Res. 1998 Apr;22(4):373–378. doi: 10.1016/s0145-2126(98)00011-3. [DOI] [PubMed] [Google Scholar]
  7. GEHAN E. A. The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis. 1961 Apr;13:346–353. doi: 10.1016/0021-9681(61)90060-1. [DOI] [PubMed] [Google Scholar]
  8. Gonzalez R., Ebbinghaus S., Henthorn T. K., Miller D., Kraft A. S. Treatment of patients with metastatic melanoma with bryostatin-1--a phase II study. Melanoma Res. 1999 Dec;9(6):599–606. doi: 10.1097/00008390-199912000-00010. [DOI] [PubMed] [Google Scholar]
  9. Hickman P. F., Kemp G. J., Thompson C. H., Salisbury A. J., Wade K., Harris A. L., Radda G. K. Bryostatin 1, a novel antineoplastic agent and protein kinase C activator, induces human myalgia and muscle metabolic defects: a 31P magnetic resonance spectroscopic study. Br J Cancer. 1995 Oct;72(4):998–1003. doi: 10.1038/bjc.1995.449. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hornung R. L., Pearson J. W., Beckwith M., Longo D. L. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity. Cancer Res. 1992 Jan 1;52(1):101–107. [PubMed] [Google Scholar]
  11. Jayson G. C., Crowther D., Prendiville J., McGown A. T., Scheid C., Stern P., Young R., Brenchley P., Chang J., Owens S. A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion. Br J Cancer. 1995 Aug;72(2):461–468. doi: 10.1038/bjc.1995.356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Khan P., McGown A. T., Dawson M. J., Jayson G., Prendiville J. A., Pettit G. R., Crowther D. High-performance liquid chromatographic assay for the novel antitumor drug, bryostatin-1, incorporating a serum extraction technique. J Chromatogr B Biomed Sci Appl. 1998 May 8;709(1):113–117. doi: 10.1016/s0378-4347(98)00007-3. [DOI] [PubMed] [Google Scholar]
  13. Koutcher J. A., Motwani M., Zakian K. L., Li X. K., Matei C., Dyke J. P., Ballon D., Yoo H. H., Schwartz G. K. The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow. Clin Cancer Res. 2000 Apr;6(4):1498–1507. [PubMed] [Google Scholar]
  14. Maki A., Diwakaran H., Redman B., al-Asfar S., Pettit G. R., Mohammad R. M., al-Katib A. The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma. Anticancer Drugs. 1995 Jun;6(3):392–397. doi: 10.1097/00001813-199506000-00005. [DOI] [PubMed] [Google Scholar]
  15. May W. S., Sharkis S. J., Esa A. H., Gebbia V., Kraft A. S., Pettit G. R., Sensenbrenner L. L. Antineoplastic bryostatins are multipotential stimulators of human hematopoietic progenitor cells. Proc Natl Acad Sci U S A. 1987 Dec;84(23):8483–8487. doi: 10.1073/pnas.84.23.8483. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. McGown A. T., Jayson G., Pettit G. R., Haran M. S., Ward T. H., Crowther D. Bryostatin 1-tamoxifen combinations show synergistic effects on the inhibition of growth of P388 cells in vitro. Br J Cancer. 1998;77(2):216–220. doi: 10.1038/bjc.1998.36. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  18. Mohammad R. M., Beck F. W., Katato K., Hamdy N., Wall N., Al-Katib A. Potentiation of 2-chlorodeoxyadenosine activity by bryostatin 1 in the resistant chronic lymphocytic leukemia cell line (WSU-CLL): association with increased ratios of dCK/5'-NT and Bax/Bcl-2. Biol Chem. 1998 Oct;379(10):1253–1261. doi: 10.1515/bchm.1998.379.10.1253. [DOI] [PubMed] [Google Scholar]
  19. Mohammad R. M., Diwakaran H., Maki A., Emara M. A., Pettit G. R., Redman B., al-Katib A. Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma. Leuk Res. 1995 Sep;19(9):667–673. doi: 10.1016/0145-2126(95)00037-o. [DOI] [PubMed] [Google Scholar]
  20. Mohammad R. M., al-Katib A., Pettit G. R., Sensenbrenner L. L. Differential effects of bryostatin 1 on human non-Hodgkin's B-lymphoma cell lines. Leuk Res. 1993 Jan;17(1):1–8. doi: 10.1016/0145-2126(93)90134-7. [DOI] [PubMed] [Google Scholar]
  21. Mohammad R. M., al-Katib A., Pettit G. R., Sensenbrenner L. L. Successful treatment of human Waldenström's macroglobulinemia with combination biological and chemotherapy agents. Cancer Res. 1994 Jan 1;54(1):165–168. [PubMed] [Google Scholar]
  22. Nishizuka Y. Studies and perspectives of protein kinase C. Science. 1986 Jul 18;233(4761):305–312. doi: 10.1126/science.3014651. [DOI] [PubMed] [Google Scholar]
  23. Philip P. A., Rea D., Thavasu P., Carmichael J., Stuart N. S., Rockett H., Talbot D. C., Ganesan T., Pettit G. R., Balkwill F. Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee. J Natl Cancer Inst. 1993 Nov 17;85(22):1812–1818. doi: 10.1093/jnci/85.22.1812. [DOI] [PubMed] [Google Scholar]
  24. Prendiville J., Crowther D., Thatcher N., Woll P. J., Fox B. W., McGown A., Testa N., Stern P., McDermott R., Potter M. A phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br J Cancer. 1993 Aug;68(2):418–424. doi: 10.1038/bjc.1993.352. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Propper D. J., Macaulay V., O'Byrne K. J., Braybrooke J. P., Wilner S. M., Ganesan T. S., Talbot D. C., Harris A. L. A phase II study of bryostatin 1 in metastatic malignant melanoma. Br J Cancer. 1998 Nov;78(10):1337–1341. doi: 10.1038/bjc.1998.680. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Scheid C., Prendiville J., Jayson G., Crowther D., Fox B., Pettit G. R., Stern P. L. Immunomodulation in patients receiving intravenous Bryostatin 1 in a phase I clinical study: comparison with effects of Bryostatin 1 on lymphocyte function in vitro. Cancer Immunol Immunother. 1994 Oct;39(4):223–230. doi: 10.1007/BF01525985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Sharkis S. J., Jones R. J., Bellis M. L., Demetri G. D., Griffin J. D., Civin C., May W. S. The action of bryostatin on normal human hematopoietic progenitors is mediated by accessory cell release of growth factors. Blood. 1990 Aug 15;76(4):716–720. [PubMed] [Google Scholar]
  28. Stansfeld A. G., Diebold J., Noel H., Kapanci Y., Rilke F., Kelényi G., Sundstrom C., Lennert K., van Unnik J. A., Mioduszewska O. Updated Kiel classification for lymphomas. Lancet. 1988 Feb 6;1(8580):292–293. doi: 10.1016/s0140-6736(88)90367-4. [DOI] [PubMed] [Google Scholar]
  29. Thompson C. H., Macaulay V. M., O'Byrne K. J., Kemp G. J., Wilner S. M., Talbot D. C., Harris A. L., Radda G. K. Modulation of bryostatin 1 muscle toxicity by nifedipine: effects on muscle metabolism and oxygen supply. Br J Cancer. 1996 May;73(10):1161–1165. doi: 10.1038/bjc.1996.224. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Varterasian M. L., Mohammad R. M., Eilender D. S., Hulburd K., Rodriguez D. H., Pemberton P. A., Pluda J. M., Dan M. D., Pettit G. R., Chen B. D. Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia. J Clin Oncol. 1998 Jan;16(1):56–62. doi: 10.1200/JCO.1998.16.1.56. [DOI] [PubMed] [Google Scholar]
  31. Varterasian M. L., Mohammad R. M., Shurafa M. S., Hulburd K., Pemberton P. A., Rodriguez D. H., Spadoni V., Eilender D. S., Murgo A., Wall N. Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Clin Cancer Res. 2000 Mar;6(3):825–828. [PubMed] [Google Scholar]
  32. Weitman S., Langevin A. M., Berkow R. L., Thomas P. J., Hurwitz C. A., Kraft A. S., Dubowy R. L., Smith D. L., Bernstein M. A Phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study. Clin Cancer Res. 1999 Sep;5(9):2344–2348. [PubMed] [Google Scholar]
  33. Wojtowicz-Praga S. M., Dickson R. B., Hawkins M. J. Matrix metalloproteinase inhibitors. Invest New Drugs. 1997;15(1):61–75. doi: 10.1023/a:1005722729132. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES